This pathway is targeted by tamoxifen, selective estrogen receptor modulator, and anastrozole or letrozole, two FDA-approved aromatase inhibitors to treat HR+ breast cancer (Fig. 2) [53, 54]. This evidence concerns the gene ESR1 and breast carcinoma.